The global blood preparation market was estimated to be USD 48.19 billion in 2023 and is expected to reach at USD 96.14 billion by 2034 with a CAGR of 6.48% during the forecast period 2024-2034. Growing occurrence of blood-related disorders, rising number of transfusion procedures, surge in blood donations, increasing widespread utilization of blood & its derivatives in various surgeries, growing number of accidents, rising prevalence of chronic diseases, surge in advancements in healthcare technologies, heightened research & development efforts on preparation methods, increasing introduction of innovative technologies, rising utilization of plasma in the pharmaceutical industry, increasing establishment of new blood bank centers, and heightened focus on the development of novel blood preparation products are some of the key factors boosting the market growth.
Heightened focus on the development of novel blood preparation products is predicted to boost the market growth during the forecast period. Blood components are substances derived from platelet-rich plasma or whole blood, including platelets, plasma, red blood cells, and white blood cells. These components are separated from whole blood through phlebotomy or hemapheresis using differential centrifugation techniques. Hospital laboratories and blood centers extract these components and provide them to patients requiring transfusions for various diseases. For instance, in February 2022, BAyer AG has secured fast-track designation from US drug regulators for a novel blood thinner aimed at preventing specific types of strokes, as it endeavors to replicate the success achieved with its anticoagulant, Xarelto.
By product, whole blood was the highest revenue-grossing segment in the global blood preparation market in 2023 owing to the growing need for significant surgical procedures & transfusions, coupled with the benefits of easy accessibility, affordability, and minimal maintenance. Additionally, blood derivatives is predicted to grow at the fastest CAGR during the forecast period owing to the government initiatives are being implemented to promote the advancement of plasma-derived proteins, including immunoglobulins, coagulation factor products, human fibrin foam, dried human plasma, and human thrombin. For instance, in August 2022, The Department of Health and Human Services has initiated a new campaign called "Giving = Living," aimed at boosting blood and plasma donations across the United States.
By type, anticoagulants was the highest revenue-grossing segment in the global blood preparation market in 2023 owing to the rising trend of new product introductions, increasing incidence of cardiac conditions, ongoing research & development efforts, and surge in collaborations among industry participants. For instance, in May 2023, Endo has entered into agreements with Gland Pharma Limited and MAIA Pharmaceuticals, Inc. to market bivalirudin, an anticoagulant (thrombin inhibitor) aimed at preventing clot formation in the U.S. market. Additionally, fibrinolytics is predicted to grow at the fastest CAGR during the forecast period owing to the rising launch of novel & more efficient anticoagulant drugs by biopharmaceutical companies and growing focus on the development of innovative products.
By application, thrombocytosis was the highest revenue-grossing segment in the global blood preparation market in 2023 owing to the rising incidence of thrombocytosis, increased awareness & diagnosis of the condition, surge in advancements in diagnostic methods, growing development of targeted therapies & innovative treatment options for thrombocytosis. For instance, in May 2023, Bayer has been granted fast track designation by the U.S. FDA for asundexian, currently in Phase III of the OCEANIC clinical trial program. This drug offers a new approach to thrombosis management, aiming to separate effectiveness from heightened bleeding risks. Additionally, angina blood vessel complications is predicted to grow at the fastest CAGR during the forecast period owing to the growing focus on research & development efforts aimed at creating anticoagulants for cardiac issues, increasing prevalence of Cardiovascular Disorders (CVDs) and the surge in lifestyle-related illnesses.
North America region is anticipated for the highest revenue share during the forecast period owing to the rise in the occurrence of Cardiovascular Disorders (CVDs), leukemia, hematological, & neurological ailments, heightened patient awareness, increase in healthcare spending, the existence of advanced healthcare facilities, and growing financial support from leading industry players. For instance, in May 2023, NYBC Ventures introduced a $50 million fund aimed at expediting advancements in blood and cellular therapies. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in the enhancement of healthcare infrastructure, spurred by initiatives from both private and public organizations, rising trend of introducing new therapies, and growing approvals from regulatory bodies. For instance, in February 2023, Terumo Blood and Cell Technologies revealed that its IMUGARD WB Platelet Pooling Set has obtained FDA clearance and is now officially available. This innovative platelet pooling set allows for the extension of the shelf life of platelets derived from whole blood, from 5 days to 7 days. IMUGARD stands as the initial platelet pooling set to receive approval for 7-day storage in the United States.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Heightened focus on the development of novel blood preparation products is predicted to boost the market growth during the forecast period. Blood components are substances derived from platelet-rich plasma or whole blood, including platelets, plasma, red blood cells, and white blood cells. These components are separated from whole blood through phlebotomy or hemapheresis using differential centrifugation techniques. Hospital laboratories and blood centers extract these components and provide them to patients requiring transfusions for various diseases. For instance, in February 2022, BAyer AG has secured fast-track designation from US drug regulators for a novel blood thinner aimed at preventing specific types of strokes, as it endeavors to replicate the success achieved with its anticoagulant, Xarelto.
By product, whole blood was the highest revenue-grossing segment in the global blood preparation market in 2023 owing to the growing need for significant surgical procedures & transfusions, coupled with the benefits of easy accessibility, affordability, and minimal maintenance. Additionally, blood derivatives is predicted to grow at the fastest CAGR during the forecast period owing to the government initiatives are being implemented to promote the advancement of plasma-derived proteins, including immunoglobulins, coagulation factor products, human fibrin foam, dried human plasma, and human thrombin. For instance, in August 2022, The Department of Health and Human Services has initiated a new campaign called "Giving = Living," aimed at boosting blood and plasma donations across the United States.
By type, anticoagulants was the highest revenue-grossing segment in the global blood preparation market in 2023 owing to the rising trend of new product introductions, increasing incidence of cardiac conditions, ongoing research & development efforts, and surge in collaborations among industry participants. For instance, in May 2023, Endo has entered into agreements with Gland Pharma Limited and MAIA Pharmaceuticals, Inc. to market bivalirudin, an anticoagulant (thrombin inhibitor) aimed at preventing clot formation in the U.S. market. Additionally, fibrinolytics is predicted to grow at the fastest CAGR during the forecast period owing to the rising launch of novel & more efficient anticoagulant drugs by biopharmaceutical companies and growing focus on the development of innovative products.
By application, thrombocytosis was the highest revenue-grossing segment in the global blood preparation market in 2023 owing to the rising incidence of thrombocytosis, increased awareness & diagnosis of the condition, surge in advancements in diagnostic methods, growing development of targeted therapies & innovative treatment options for thrombocytosis. For instance, in May 2023, Bayer has been granted fast track designation by the U.S. FDA for asundexian, currently in Phase III of the OCEANIC clinical trial program. This drug offers a new approach to thrombosis management, aiming to separate effectiveness from heightened bleeding risks. Additionally, angina blood vessel complications is predicted to grow at the fastest CAGR during the forecast period owing to the growing focus on research & development efforts aimed at creating anticoagulants for cardiac issues, increasing prevalence of Cardiovascular Disorders (CVDs) and the surge in lifestyle-related illnesses.
North America region is anticipated for the highest revenue share during the forecast period owing to the rise in the occurrence of Cardiovascular Disorders (CVDs), leukemia, hematological, & neurological ailments, heightened patient awareness, increase in healthcare spending, the existence of advanced healthcare facilities, and growing financial support from leading industry players. For instance, in May 2023, NYBC Ventures introduced a $50 million fund aimed at expediting advancements in blood and cellular therapies. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in the enhancement of healthcare infrastructure, spurred by initiatives from both private and public organizations, rising trend of introducing new therapies, and growing approvals from regulatory bodies. For instance, in February 2023, Terumo Blood and Cell Technologies revealed that its IMUGARD WB Platelet Pooling Set has obtained FDA clearance and is now officially available. This innovative platelet pooling set allows for the extension of the shelf life of platelets derived from whole blood, from 5 days to 7 days. IMUGARD stands as the initial platelet pooling set to receive approval for 7-day storage in the United States.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Type, and Application
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Blood Preparation Market Report 2023 - 2034
Blood Preparation Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Blood Derivatives
- Whole Blood
- Granulocytes
- Platelets
- Red Cells
- Plasma
- Blood Components
- Leukocyte Reduced Red Blood Cells
- Whole Blood Components
- Platelet Concentrate
- Packed Red Cells
- Frozen Plasma
- Cryoprecipitate
Blood Preparation Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Fibrinolytics
- Tissue Plasminogen Activator (tPA)
- Streptokinase
- Urokinase
- Platelet Aggregation Inhibitors
- Glycoprotein Inhibitors
- ADP Antagonists
- COX Inhibitors
- Others
- Anticoagulants
- Direct Factor Xa Inhibitors
- Direct Thrombin Inhibitors
- Vitamin K Antagonists
- Heparins
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin
- Unfractionated Heparin
Blood Preparation Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Angina Blood Vessel Complications
- Pulmonary Embolism
- Renal Impairment
- Thrombocytosis
- Others
Blood Preparation Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Blood Preparation Market: Product Estimates & Trend Analysis
8. Blood Preparation Market: Type Estimates & Trend Analysis
9. Blood Preparation Market: Application Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Blood Preparation Market
12. Europe Global Blood Preparation Market
13. Asia Pacific Global Blood Preparation Market
14. Latin America Global Blood Preparation Market
15. MEA Global Blood Preparation Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Shandong East Chemical Industry Co.
- AstraZeneca plc
- GlaxoSmithKline PLC
- Portola Pharmaceuticals Inc.
- Sanofi
- Celgene Corp.
- Bristol-Myers Squibb Company
- Pfizer Inc
- Baxter International Inc
- Leo Pharma A/S
- Xiamen Hisunny Chemical Co. Ltd
